investingdog, you say "I think that's all (50 to 100 millions upfront) they will get at this point without having BLA or some sort of accelerated approval path in the pocket."
That seems right to me, with additional payments at achievement points. Maybe they'll do better, but your view of what the company can get is not anywhere near factored into the share price, in my view.
I don't see why the company having a staff to manage expanded trials is inconsistent with a deal, though. It seems, rather, that it's signaling confidence in an upcoming deal.
Anyway, that's my view, and we'll all know the answer within a few months.
News 
Market Data 
Discover 
